Ipilimumab

Ipilumumab Feasible for Recurrent Hematologic Cancers After Allogeneic Stem Cell Transplant

Ipilumumab Feasible for Recurrent Hematologic Cancers After Allogeneic Stem Cell Transplant

By

Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).

Case Reports Show an Association Between Immune Checkpoint Inhibitors and Risk for Rheumatologic Disorders

Case Reports Show an Association Between Immune Checkpoint Inhibitors and Risk for Rheumatologic Disorders

By

A small number of patients with cancer treated with immune checkpoint inhibitors may have higher-than-usual risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a case report on 13 patients has shown.

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

By

Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.

Surgery followed by ipilimumab improves survival for patients with melanoma

By

An international study demonstrated that ipilimumab improves the relapse-free survival of patients with advanced stage melanoma who are rendered free of disease surgically but at high risk for relapse.

Nivolumab Demonstrates Consistent Adverse Event Profile for Recurrent Glioblastoma

Nivolumab Demonstrates Consistent Adverse Event Profile for Recurrent Glioblastoma

By

The adverse event profile of nivolumab with or without ipilimumab in patients with glioblastoma was encouraging.

Adjuvant ipilimumab improves survival after high-risk lymph node and melanoma resection

By

Adjuvant ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but is also associated with a high rate of adverse events.

Immunotherapy shows clinical benefit in relapsed transplant recipients

Immunotherapy shows clinical benefit in relapsed transplant recipients

By

Almost half of patients with blood cancer who had relapsed following allogeneic stem cell transplantation benefitted from treatment with the immune checkpoint blocker ipilimumab.

Combination therapy for advanced melanoma found to increase survival

Combination therapy for advanced melanoma found to increase survival

Pairing ipilimumab with sargramostim gives patients about five extra months survival time for patients with advanced melanoma, researchers report.

Marker may predict response to ipilimumab in advanced melanoma

By

Among patients with advanced melanoma, presence of higher levels of the protein VEGF in blood was associated with poor response to treatment with the immunotherapy ipilimumab.

Biomarker may help predict melanoma survival

Biomarker may help predict melanoma survival

High pretreatment VEGF levels have been linked to lower survival after ipilimumab treatment.

ASCO: Combo antibody therapy effective for melanoma

ASCO: Combo antibody therapy effective for melanoma

Findings from a phase I study of concurrent ipilimumab and nivolumab for advanced melanoma

A clearer role for radiotherapy in high-risk melanoma

A clearer role for radiotherapy in high-risk melanoma

By

A new study suggests radiotherapy may hold clinical promise for the control of local lymph node bed recurrence of malignant melanoma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs